HEADER ANTITUMOR PROTEIN 05-MAY-19 6K05 TITLE CRYSTAL STRUCTURE OF BRD2(BD1)WITH LIGAND BY27 BOUND COMPND MOL_ID: 1; COMPND 2 MOLECULE: BROMODOMAIN-CONTAINING PROTEIN 2; COMPND 3 CHAIN: A, B, C; COMPND 4 SYNONYM: O27.1.1,REALLY INTERESTING NEW GENE 3 PROTEIN; COMPND 5 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: BRD2, KIAA9001, RING3; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS ANTITUMOR; BET PROTEINS; BROMODOMAIN INHIBITOR; EPIGENETIC READERS, KEYWDS 2 ANTITUMOR PROTEIN EXPDTA X-RAY DIFFRACTION AUTHOR T.LU,W.LU,D.CHEN,Y.ZHAO,C.LUO REVDAT 3 22-NOV-23 6K05 1 REMARK REVDAT 2 25-SEP-19 6K05 1 REMARK REVDAT 1 18-SEP-19 6K05 0 JRNL AUTH D.CHEN,T.LU,Z.YAN,W.LU,F.ZHOU,X.LYU,B.XU,H.JIANG,K.CHEN, JRNL AUTH 2 C.LUO,Y.ZHAO JRNL TITL DISCOVERY, STRUCTURAL INSIGHT, AND BIOACTIVITIES OF BY27 AS JRNL TITL 2 A SELECTIVE INHIBITOR OF THE SECOND BROMODOMAINS OF BET JRNL TITL 3 PROTEINS. JRNL REF EUR.J.MED.CHEM. V. 182 11633 2019 JRNL REFN ISSN 0223-5234 JRNL PMID 31461688 JRNL DOI 10.1016/J.EJMECH.2019.111633 REMARK 2 REMARK 2 RESOLUTION. 1.94 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX 1.10.1_2155 REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.94 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 45.38 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.360 REMARK 3 COMPLETENESS FOR RANGE (%) : 96.4 REMARK 3 NUMBER OF REFLECTIONS : 30852 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.186 REMARK 3 R VALUE (WORKING SET) : 0.185 REMARK 3 FREE R VALUE : 0.210 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.850 REMARK 3 FREE R VALUE TEST SET COUNT : 1497 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 45.3939 - 4.3013 0.99 2815 145 0.1751 0.1932 REMARK 3 2 4.3013 - 3.4145 0.98 2761 121 0.1601 0.1751 REMARK 3 3 3.4145 - 2.9829 1.00 2778 146 0.1944 0.2155 REMARK 3 4 2.9829 - 2.7103 0.97 2668 161 0.1906 0.2333 REMARK 3 5 2.7103 - 2.5160 1.00 2734 155 0.1875 0.2108 REMARK 3 6 2.5160 - 2.3677 1.00 2735 136 0.1905 0.2128 REMARK 3 7 2.3677 - 2.2491 1.00 2770 145 0.1896 0.2033 REMARK 3 8 2.2491 - 2.1512 0.98 2717 127 0.1957 0.2706 REMARK 3 9 2.1512 - 2.0684 0.98 2697 125 0.2153 0.2745 REMARK 3 10 2.0684 - 1.9970 1.00 2765 123 0.2407 0.2594 REMARK 3 11 1.9970 - 1.9346 0.70 1915 113 0.2946 0.3314 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : NULL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.240 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 22.830 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.007 2822 REMARK 3 ANGLE : 0.974 3828 REMARK 3 CHIRALITY : 0.047 398 REMARK 3 PLANARITY : 0.005 473 REMARK 3 DIHEDRAL : 12.486 1674 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 6K05 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBJ ON 13-MAY-19. REMARK 100 THE DEPOSITION ID IS D_1300012054. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 06-JAN-19 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SSRF REMARK 200 BEAMLINE : BL19U1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.97849 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-3000 REMARK 200 DATA SCALING SOFTWARE : AIMLESS REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 30866 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.935 REMARK 200 RESOLUTION RANGE LOW (A) : 45.381 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 96.6 REMARK 200 DATA REDUNDANCY : 6.700 REMARK 200 R MERGE (I) : 0.11400 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 19.7800 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.94 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.01 REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.73500 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: 2YEK REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 50.50 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.48 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 25-30% PEG MME 5000, 0.2M AMMONIUM REMARK 280 SULFATE, 0.1M MES PH 6.7, VAPOR DIFFUSION, SITTING DROP, REMARK 280 TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 57.56650 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 27.86750 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 57.56650 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 27.86750 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 2100 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 11540 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -12.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1920 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 11410 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -9.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: C REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 BIOMT1 2 -1.000000 0.000000 0.000000 -5.09132 REMARK 350 BIOMT2 2 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 2 0.000000 0.000000 -1.000000 67.24153 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 73 REMARK 465 ARG A 74 REMARK 465 VAL A 75 REMARK 465 GLU A 184 REMARK 465 GLN A 185 REMARK 465 GLU A 186 REMARK 465 LEU A 187 REMARK 465 VAL A 188 REMARK 465 VAL A 189 REMARK 465 THR A 190 REMARK 465 ILE A 191 REMARK 465 PRO A 192 REMARK 465 LYS A 193 REMARK 465 ASN A 194 REMARK 465 GLY B 73 REMARK 465 ARG B 74 REMARK 465 VAL B 75 REMARK 465 GLU B 183 REMARK 465 GLU B 184 REMARK 465 GLN B 185 REMARK 465 GLU B 186 REMARK 465 LEU B 187 REMARK 465 VAL B 188 REMARK 465 VAL B 189 REMARK 465 THR B 190 REMARK 465 ILE B 191 REMARK 465 PRO B 192 REMARK 465 LYS B 193 REMARK 465 ASN B 194 REMARK 465 GLY C 73 REMARK 465 ARG C 74 REMARK 465 VAL C 75 REMARK 465 GLN C 182 REMARK 465 GLU C 183 REMARK 465 GLU C 184 REMARK 465 GLN C 185 REMARK 465 GLU C 186 REMARK 465 LEU C 187 REMARK 465 VAL C 188 REMARK 465 VAL C 189 REMARK 465 THR C 190 REMARK 465 ILE C 191 REMARK 465 PRO C 192 REMARK 465 LYS C 193 REMARK 465 ASN C 194 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLN A 101 CG CD OE1 NE2 REMARK 470 GLN A 182 CG CD OE1 NE2 REMARK 470 GLU A 183 CG CD OE1 OE2 REMARK 470 LYS C 88 CG CD CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LEU B 110 79.70 -116.42 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue CQF A 201 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue CQF B 201 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue MES B 202 DBREF 6K05 A 73 194 UNP P25440 BRD2_HUMAN 73 194 DBREF 6K05 B 73 194 UNP P25440 BRD2_HUMAN 73 194 DBREF 6K05 C 73 194 UNP P25440 BRD2_HUMAN 73 194 SEQRES 1 A 122 GLY ARG VAL THR ASN GLN LEU GLN TYR LEU HIS LYS VAL SEQRES 2 A 122 VAL MET LYS ALA LEU TRP LYS HIS GLN PHE ALA TRP PRO SEQRES 3 A 122 PHE ARG GLN PRO VAL ASP ALA VAL LYS LEU GLY LEU PRO SEQRES 4 A 122 ASP TYR HIS LYS ILE ILE LYS GLN PRO MET ASP MET GLY SEQRES 5 A 122 THR ILE LYS ARG ARG LEU GLU ASN ASN TYR TYR TRP ALA SEQRES 6 A 122 ALA SER GLU CYS MET GLN ASP PHE ASN THR MET PHE THR SEQRES 7 A 122 ASN CYS TYR ILE TYR ASN LYS PRO THR ASP ASP ILE VAL SEQRES 8 A 122 LEU MET ALA GLN THR LEU GLU LYS ILE PHE LEU GLN LYS SEQRES 9 A 122 VAL ALA SER MET PRO GLN GLU GLU GLN GLU LEU VAL VAL SEQRES 10 A 122 THR ILE PRO LYS ASN SEQRES 1 B 122 GLY ARG VAL THR ASN GLN LEU GLN TYR LEU HIS LYS VAL SEQRES 2 B 122 VAL MET LYS ALA LEU TRP LYS HIS GLN PHE ALA TRP PRO SEQRES 3 B 122 PHE ARG GLN PRO VAL ASP ALA VAL LYS LEU GLY LEU PRO SEQRES 4 B 122 ASP TYR HIS LYS ILE ILE LYS GLN PRO MET ASP MET GLY SEQRES 5 B 122 THR ILE LYS ARG ARG LEU GLU ASN ASN TYR TYR TRP ALA SEQRES 6 B 122 ALA SER GLU CYS MET GLN ASP PHE ASN THR MET PHE THR SEQRES 7 B 122 ASN CYS TYR ILE TYR ASN LYS PRO THR ASP ASP ILE VAL SEQRES 8 B 122 LEU MET ALA GLN THR LEU GLU LYS ILE PHE LEU GLN LYS SEQRES 9 B 122 VAL ALA SER MET PRO GLN GLU GLU GLN GLU LEU VAL VAL SEQRES 10 B 122 THR ILE PRO LYS ASN SEQRES 1 C 122 GLY ARG VAL THR ASN GLN LEU GLN TYR LEU HIS LYS VAL SEQRES 2 C 122 VAL MET LYS ALA LEU TRP LYS HIS GLN PHE ALA TRP PRO SEQRES 3 C 122 PHE ARG GLN PRO VAL ASP ALA VAL LYS LEU GLY LEU PRO SEQRES 4 C 122 ASP TYR HIS LYS ILE ILE LYS GLN PRO MET ASP MET GLY SEQRES 5 C 122 THR ILE LYS ARG ARG LEU GLU ASN ASN TYR TYR TRP ALA SEQRES 6 C 122 ALA SER GLU CYS MET GLN ASP PHE ASN THR MET PHE THR SEQRES 7 C 122 ASN CYS TYR ILE TYR ASN LYS PRO THR ASP ASP ILE VAL SEQRES 8 C 122 LEU MET ALA GLN THR LEU GLU LYS ILE PHE LEU GLN LYS SEQRES 9 C 122 VAL ALA SER MET PRO GLN GLU GLU GLN GLU LEU VAL VAL SEQRES 10 C 122 THR ILE PRO LYS ASN HET CQF A 201 50 HET CQF B 201 50 HET MES B 202 25 HETNAM CQF (6~{R})-~{N}-(4-CHLOROPHENYL)-1-METHYL-8-(1- HETNAM 2 CQF METHYLPYRAZOL-4-YL)-5,6-DIHYDRO-4~{H}-[1,2, HETNAM 3 CQF 4]TRIAZOLO[4,3-A][1]BENZAZEPIN-6-AMINE HETNAM MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID FORMUL 4 CQF 2(C22 H21 CL N6) FORMUL 6 MES C6 H13 N O4 S FORMUL 7 HOH *174(H2 O) HELIX 1 AA1 THR A 76 VAL A 85 1 10 HELIX 2 AA2 VAL A 85 LYS A 92 1 8 HELIX 3 AA3 ALA A 96 ARG A 100 5 5 HELIX 4 AA4 ASP A 104 GLY A 109 1 6 HELIX 5 AA5 ASP A 112 ILE A 117 1 6 HELIX 6 AA6 ASP A 122 ASN A 132 1 11 HELIX 7 AA7 ALA A 137 ASN A 156 1 20 HELIX 8 AA8 ASP A 160 ALA A 178 1 19 HELIX 9 AA9 ASN B 77 VAL B 85 1 9 HELIX 10 AB1 VAL B 85 LYS B 92 1 8 HELIX 11 AB2 ALA B 96 ARG B 100 5 5 HELIX 12 AB3 ASP B 104 GLY B 109 1 6 HELIX 13 AB4 ASP B 112 ILE B 117 1 6 HELIX 14 AB5 ASP B 122 ASN B 132 1 11 HELIX 15 AB6 ALA B 137 ASN B 156 1 20 HELIX 16 AB7 ASP B 160 SER B 179 1 20 HELIX 17 AB8 ASN C 77 VAL C 85 1 9 HELIX 18 AB9 VAL C 85 HIS C 93 1 9 HELIX 19 AC1 ALA C 96 ARG C 100 5 5 HELIX 20 AC2 ASP C 112 ILE C 117 1 6 HELIX 21 AC3 ASP C 122 ASN C 132 1 11 HELIX 22 AC4 ALA C 137 ASN C 156 1 20 HELIX 23 AC5 ASP C 160 SER C 179 1 20 SITE 1 AC1 8 PRO A 98 PHE A 99 LYS A 107 LEU A 108 SITE 2 AC1 8 LEU A 110 ASN A 156 HOH A 311 GLN B 94 SITE 1 AC2 8 GLN A 94 TRP B 97 PRO B 98 PHE B 99 SITE 2 AC2 8 LEU B 108 LEU B 110 ASN B 156 HOH B 308 SITE 1 AC3 7 TRP B 97 ARG B 100 HOH B 342 ARG C 128 SITE 2 AC3 7 ASN C 132 TYR C 134 HOH C 221 CRYST1 115.133 55.735 67.434 90.00 94.33 90.00 C 1 2 1 12 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.008686 0.000000 0.000657 0.00000 SCALE2 0.000000 0.017942 0.000000 0.00000 SCALE3 0.000000 0.000000 0.014872 0.00000